Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;29(1):33–35. [Article in Spanish] doi: 10.1016/S0212-6567(02)70497-6

¿Es necesario pedir la antitrombina III a las mujeres que toman anticonceptivos orales?

R de Dios del Valle a,*, A Franco Vidal b
PMCID: PMC7684136  PMID: 11820961

The content is available as a PDF (301.8 KB).

Bibliografía

  • 1.Lewis M. The epidemiology of oral contraceptive use: a critical review of studies on oral contraceptives and the health of young women. Am J Obstet Gynecol. 1998;179:1086–1097. doi: 10.1016/s0002-9378(98)70220-0. [DOI] [PubMed] [Google Scholar]
  • 2.Inauen W., Baumgartner H.R., Haeberli A., Straub P.W. Excessive deposition of fibrin, platelets and platelet thrombi on vascular subendothelium during contraceptive drug treatment. Thromb Haemost. 1987;57:306–309. [PubMed] [Google Scholar]
  • 3.Pabinger I., Schneider B. Thrombotic risk of women with hereditary antithrombin III-protein C and protein S- deficiency taking oral contraceptive medication. Thrombosis and Haemostasis. 1994;71:548–552. [PubMed] [Google Scholar]
  • 4.Pérez Campos E., García Cervera J., Álvarez de Sotomayor M., Bernabeu Pérez S. Sociedad Española de Contracepción, Manual de anticoncepción hormonal oral. 1.a ed. INO Reproducciones; Zaragoza: 1997. Normas de uso: I. Pruebas previas y controles sucesivos; pp. 165–169. [Google Scholar]
  • 5.Izquierdo A. Sociedad Española de Medicina de Familia y Comunitaria. Guía de actuación en atención primaria. 2.a ed. EdiDe; Barcelona: 2000. Alteraciones de las pruebas de coagulación; pp. 1051–1053. [Google Scholar]
  • 6.Alonso Roca R. Sociedad Española de Medicina de Familia y Comunitaria. Guía de actuación en atención primaria. 2.a ed. EdiDe; Barcelona: 2000. Planificación familiar; pp. 285–290. [Google Scholar]
  • 7.Palareti G., Legnani C., Frascaro M., Flamigni C., Gammi L., Gola G. Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. Contraception. 1999;59:293–299. doi: 10.1016/s0010-7824(99)00033-5. [DOI] [PubMed] [Google Scholar]
  • 8.Winkler U. Blood coagulation and oral contraceptives. Contraception. 1998;57:203–209. doi: 10.1016/s0010-7824(98)00020-1. [DOI] [PubMed] [Google Scholar]
  • 9.Vandenbroucke J.P., Van der Meer F.J.M., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 1996;313:1127–1130. doi: 10.1136/bmj.313.7065.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nachman R.L., Silverstein R. Hypercoagulable states. Ann Intern Med. 1993;119:819–882. doi: 10.7326/0003-4819-119-8-199310150-00008. [DOI] [PubMed] [Google Scholar]
  • 11.Heijboer H., Brandjes D., Büller H., Sturk A., Wouter ten Cate J. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512–1516. doi: 10.1056/NEJM199011293232202. [DOI] [PubMed] [Google Scholar]
  • 12.Pabinger I., Brücker S., Kyrle P.A., Schneider B., Korninger H.C., Niessner H. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibrinol. 1992;3:547–553. [PubMed] [Google Scholar]
  • 13.Schambeck C.M., Schwender S., Haubitz I., Geisen U.E., Grossmann R.E., Keller F. Selective screening for the factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost. 1997;78:1480–1483. [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES